Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).